Neurocrine Biosciences Starts Phase 2 Clinical Trial Of NBI-1117567 To Treat Adults With Mild To Moderate Alzheimer's Disease

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has commenced a Phase 2 clinical trial for its investigational compound NBI-1117567, aimed at treating adults with mild to moderate Alzheimer's disease. NBI-1117567 is an orally administered selective muscarinic agonist, specifically targeting M1/M4 receptors, and is being evaluated as an adjunctive treatment for cognitive impairment associated with the disease.